Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 108.94M | 109.85M | 93.59M | 111.53M | 107.48M | 86.68M |
Gross Profit | 15.81M | 17.97M | 11.01M | 18.05M | 17.40M | 16.57M |
EBITDA | 8.77M | 14.44M | 6.02M | 14.13M | 14.19M | 12.88M |
Net Income | 2.25M | 7.46M | 508.78K | 9.13M | 8.37M | 6.35M |
Balance Sheet | ||||||
Total Assets | 89.38M | 96.09M | 78.45M | 72.00M | 64.99M | 54.06M |
Cash, Cash Equivalents and Short-Term Investments | 10.77M | 8.96M | 799.13K | 7.53M | 8.47M | 3.22M |
Total Debt | 8.94M | 10.13M | 11.41M | 8.03M | 9.57M | 9.79M |
Total Liabilities | 25.56M | 31.42M | 22.59M | 16.85M | 19.92M | 18.08M |
Stockholders Equity | 63.81M | 64.67M | 55.86M | 55.15M | 45.07M | 35.98M |
Cash Flow | ||||||
Free Cash Flow | 13.08M | 12.03M | -7.58M | 2.67M | 5.58M | 10.30M |
Operating Cash Flow | 16.47M | 15.79M | 5.44M | 17.27M | 8.05M | 11.96M |
Investing Cash Flow | -3.37M | -3.75M | -13.02M | -14.60M | -2.47M | -1.61M |
Financing Cash Flow | -3.19M | -3.93M | 859.92K | -3.62M | -304.06K | -7.16M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
71 Outperform | C$2.51B | 13.12 | 11.97% | 7.77% | 4.69% | 4.54% | |
58 Neutral | C$58.86M | 26.22 | 3.58% | ― | 6.69% | -49.29% | |
58 Neutral | C$95.05M | -6.13 | -13.82% | 16.80% | -3.54% | -244.21% | |
57 Neutral | C$968.02M | -120.71 | -0.48% | 5.02% | 2.77% | 81.01% | |
53 Neutral | C$77.43M | 11.29 | 19.17% | 5.36% | -8.92% | ― | |
41 Neutral | C$43.13M | -3.95 | 192.72% | ― | 0.58% | 45.10% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% |
Imaflex Inc. reported a decrease in revenues and adjusted net income for Q2 2025 compared to the previous year, with revenues at $26.4 million and adjusted net income at $1.0 million. Despite these challenges, the company maintained a strong balance sheet with no long-term debt and increased cash levels, highlighting its resilience and strategic focus on sustainable growth amid market uncertainties.
The most recent analyst rating on (TSE:IFX) stock is a Buy with a C$1.50 price target. To see the full list of analyst forecasts on Imaflex stock, see the TSE:IFX Stock Forecast page.
Imaflex Inc. reported its Q2 2025 financial results, showing a decline in revenues to $26.4 million from $28.8 million in the previous year, primarily due to pricing adjustments and lower volumes. Despite these challenges, the company maintained a solid balance sheet with $22.8 million in liquidity and no long-term debt, demonstrating resilience and operational agility. The company plans to focus on strategic execution, talent development, and product innovation to drive sustainable growth amid ongoing pricing pressures and economic risks.
The most recent analyst rating on (TSE:IFX) stock is a Buy with a C$1.50 price target. To see the full list of analyst forecasts on Imaflex stock, see the TSE:IFX Stock Forecast page.